

Minutes: Steering Board meeting, 4 and 6 January 2021

Meeting with Modena representatives

Moderna representatives held a comprehensive presentation to the Members of the Steering Board on the:

1. **Subcontractor legal documentation,** [REDACTED]

2. **Product release to the EU Member States**

The Company presented the **overall manufacturing and release process**, outlining the general process overview.

In this context, Moderna representatives presented details as regards the:

- shipment;
- in-country receipt;
- release of the product;
- the transport concept;
- details on the transport equipment trailers and equipment;
- vaccines transport warehouse to customer.

3. **Estimated delivery schedule**

The representatives of the Company presented a comprehensive table with delivery schedule for each Member State [REDACTED]

The presentation was followed by an exchange between the Members of the SB and the representatives of the Company.

The ordinary **Steering Board** meeting started with a follow-up discussion on Moderna.

[REDACTED]

Subsequently, the Steering Committee held an in depth discussion on the top-up for Pfizer/Biontech (top up= beyond the [REDACTED] additional doses)

The Member States had already expressed a strong interest in the top-up in previous discussions/feedback reflected in the [REDACTED].

In a *tour de table* the Member States were asked once again to confirm their interest in the top-up and indicate the top-up volume each is interested in, as to have a clear picture that would allow the Commission to advance in discussions with the company both on the number of doses and the schedule for the top-up delivery.

The tour de table outlined that the interest of the Member States in the top-up went well beyond the [REDACTED] doses, for which the Commission had initially been given the mandate to start exploratory discussions with the Company.

The Members also expressed a strong interest for the top-up doses to be delivered as soon as possible, stressing that the calendar proposed during the first exploratory discussions ([REDACTED] - [REDACTED]) was not satisfactory enough.

The Members acknowledged that the delivery timeline was directly linked to the number of doses [REDACTED]

Therefore, the Commission was mandated to continue the exploratory talks for an agreement for a much larger top-up volume [REDACTED].

[REDACTED] and [REDACTED] deplored the fact that, despite various calls to the Member States, they had received [REDACTED]

[REDACTED] While wanting to ensure solidarity, some Member States expressed concerns that:

- (i) [REDACTED]
- (ii) the resubmission of new Order Forms would delay the delivery schedule of the optional doses.

A possible solution that was explored was to satisfy the needs of additional doses of the [REDACTED] Member States through [REDACTED]

[REDACTED] pleaded for solidarity in light of the extraordinary circumstances caused by an [REDACTED] [REDACTED] was reassured of the help from the MSs regarding extra doses.

Exceptional Steering Board - 6th of January

Update [REDACTED] and implementation of contracts

The exceptional Steering Board on the 6th of January meeting was organized to continue the discussions on [REDACTED].

During this session, another discussion was held amongst the Member States to accommodate changes in the allocation tables for the optional doses of the Pfizer/BioNtech and Moderna vaccine.

The discussions focused on accommodating the needs of the [REDACTED] Member States ([REDACTED]) that requested their pro-rata allocation from the [REDACTED] optional doses from BioNTech/ Pfizer after having originally declined any optional volume.

[REDACTED] pleaded again for help to the Member States for extra doses, in light of the exceptional circumstances created by the recent [REDACTED]. [REDACTED] was reassured of the help from the MSs regarding extra doses.